SCHEMBL1005550

SCHEMBL1005550

Cc1cc(C(N)=O)c(C)c(C)c1C

nearest known ligand 0.41

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 2/20 0.41
SIRT3 Q9NTG7 1/20 0.41
NNMT P40261 3/20 0.40
L3MBTL1 Q9Y468 2/20 0.38
POLB P06746 2/20 0.35
BRD4 O60885 1/20 0.35
KDM4E B2RXH2 4/20 0.35
MKNK1 Q9BUB5 1/20 0.35
MKNK2 Q9HBH9 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
PARP1 P09874 1/20 0.34
ALDH1A1 P00352 2/20 0.33
GLA P06280 2/20 0.33
GAA P10253 2/20 0.33
HPGD P15428 1/20 0.33
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2954974 0.82 POLB (0.41) TDP1SIRT3NNMTL3MBTL1POLB
SCHEMBL2128425 0.82 POLB (0.46) TDP1SIRT3NNMTL3MBTL1POLB
SCHEMBL19306320 0.82 KDM4E (0.44) TDP1SIRT3NNMTL3MBTL1BRD4
SCHEMBL27503717 0.80 TDP1 (0.37) TDP1SIRT3NNMTL3MBTL1POLB
SCHEMBL8656999 0.80 SIRT3 (0.37) TDP1SIRT3NNMTL3MBTL1POLB
SCHEMBL6748636 0.79 SIRT3 (0.46) TDP1SIRT3NNMTL3MBTL1POLB
SCHEMBL7083041 0.79 NNMT (0.50) TDP1SIRT3NNMTL3MBTL1POLB
SCHEMBL23646297 0.79 KDM4E (0.45) TDP1SIRT3NNMTL3MBTL1POLB
SCHEMBL1004219 0.79 KDM4E (0.50) TDP1SIRT3NNMTL3MBTL1KDM4E
SCHEMBL1259969 0.78 KDM4E (0.38) TDP1KDM4ESMN1; SMN2ALDH1A1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109338343-B Chemical silver plating solution and silver plating method 长沙理工大学 2020-09-25 CN claimed
JP-2011526291-A 2011-10-06 JP claimed
EP-2331526-A2 PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS IRM LLC (BM) 2011-06-15 EP claimed
US-20110112096-A1 PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS ITM LLC (BM) 2011-05-12 US claimed
WO-2009158431-A2 COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS IRM LLC (BM) 2009-12-30 WO claimed
CN-101516860-A Benzoxazoles and oxazolopyridines being useful as FANUS kinases inhibitors NOVARTIS AG (CH) 2009-08-26 CN claimed
CN-113929719-B Metal complex, organic electroluminescent element and consumer product thereof 上海八亿时空先进材料有限公司 2024-01-12 CN disclosed
CN-110198928-B Benzyloxy-pyridinyl-cyclopropanecarboxylic acid, pharmaceutical compositions and uses thereof 勃林格殷格翰国际有限公司 2023-08-29 CN disclosed
CN-116606568-A Quantum dot ink composition and quantum dot electroluminescent device 三星电子株式会社 2023-08-18 CN disclosed
CN-116056575-A Substituted haloalkylsulfonanilide herbicides FMC公司 2023-05-02 CN disclosed
CN-113929719-A Metal complex, organic electroluminescent element and consumer product thereof 上海八亿时空先进材料有限公司 2022-01-14 CN disclosed
CN-111876760-A Chemical silver plating solution for printed circuit board and preparation method of printed circuit board 广州市豪越新能源设备有限公司 2020-11-03 CN disclosed
CN-109338343-B Chemical silver plating solution and silver plating method 长沙理工大学 2020-09-25 CN disclosed
US-5891639-A Telomerase activity assays GERON CORPORATION (US) 1999-04-06 US disclosed
US-5863726-A INCUBATING CELL SAMPLE IN REACTION MIXTURE COMPRISING TELOMERASE SUBSTRATE UNDER CONDITION SUCH THAT TELOMERASE CAN CATALYZE EXTENSION OF TELOMERASE SUBSTRATE BY ADDITION OF REPEAT SEQUENCES, REPLICATING EXTENDED TELOMERASE SUBSTRATE GERON CORPORATION (US) 1999-01-26 US disclosed
US-5834193-A CONTACTING DENATURED CHROMOSOMAL DNA WITH LABELED PROBE HAVING SEQUENCE COMPLEMENTARY TO A TELOMERE REPEAT SEQUENCE UNDER CONDITIONS SUCH THAT SAID PROBE HYBRIDIZES SPECIFICALLY TO TELOMERIC DNA, MEASURING BOUND PROBE, CORRELATING WITH LENGTH GERON CORPORATION (US) 1998-11-10 US disclosed
US-5804380-A INCUBATION OF CELL SAMPLE, REPLICATION, MEASURING EXTENDED TELOMERASE SUBSTRATE, CORRELATION; KIT WITH BUFFER, PRIMER AND INSTRUCTIONS. GERON CORPORATION (US) 1998-09-08 US disclosed
EP-0774014-A1 METHODS FOR MEASURING TELOMERE LENGTH GERON CORPORATION (US) 1997-05-21 EP disclosed
WO-1997015687-A1 TELOMERASE ACTIVITY ASSAYS GERON CORPORATION (US) 1997-05-01 WO disclosed
WO-1996041016-A1 METHODS FOR MEASURING TELOMERE LENGTH GERON CORPORATION (US) 1996-12-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110112096-A1 PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS IGF1R, TYMP, PDXK TDP1 514/4885SIRT3 3816/4885NNMT 1589/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.